Actavis, Inc. (NYSE:ACT)

CAPS Rating: 4 out of 5

The Company is engaged in the development, manufacture, marketing, sale and distribution of brand and off-patent pharmaceutical products.

Results 1 - 20 of 31 : 1 2 Next »

Recs

0
Member Avatar tripleking (43.89) Submitted: 6/17/2014 10:21:35 AM : Outperform Start Price: $213.00 ACT Score: -0.72

good stock

Recs

0
Member Avatar Classical (< 20) Submitted: 3/28/2014 4:51:43 PM : Outperform Start Price: $204.27 ACT Score: -0.75

Excellent management, has not missed earnings since 2006 when the company was formally known as Watson. Growing bottom line organically and continues to cherry pick M&A that makes sense. Snaps up branded drugs coming off patent for its favorably large generic portfolio. This will be 100 billion dollar market cap if management continues its track record. Obama-care benefits this company directly because it generic line is so vast.

The founder ( Dr. Choi) started the company out of his garage!

Recs

1
Member Avatar naughtyguy (30.96) Submitted: 3/13/2014 10:43:49 AM : Underperform Start Price: $215.20 ACT Score: +5.89

34 billion market cap! You have got to be kidding!

Recs

0
Member Avatar DugdaleTiki (40.16) Submitted: 3/3/2014 9:27:18 AM : Outperform Start Price: $213.00 ACT Score: -6.19

2014 Sabrient Pick

Recs

0
Member Avatar StewpotDrew (30.93) Submitted: 2/3/2014 12:13:39 AM : Outperform Start Price: $190.00 ACT Score: +1.97

Drugs.

Recs

0
Member Avatar subsurfacemapper (57.79) Submitted: 1/22/2014 11:47:04 PM : Outperform Start Price: $186.18 ACT Score: +7.57

high RS in ibd and high comp

Recs

0
Member Avatar 1russianguy (59.91) Submitted: 1/13/2014 2:38:49 PM : Outperform Start Price: $182.54 ACT Score: +9.24

Sabrient

Recs

0
Member Avatar 1picks (84.74) Submitted: 1/13/2014 2:24:18 PM : Outperform Start Price: $182.72 ACT Score: +9.20

Sabrient

Recs

0
Member Avatar manirg (53.31) Submitted: 12/24/2013 12:28:45 PM : Outperform Start Price: $164.50 ACT Score: +22.53

Undervalued growth stock

Recs

0
Member Avatar chris293 (84.22) Submitted: 10/24/2013 5:49:57 PM : Underperform Start Price: $146.30 ACT Score: -34.22

Some of these stocks I just do not understand. A lot of negatives, for example a minus ROI, among others? O.K. they made 6 cents.

Recs

0
Member Avatar djtp54 (< 20) Submitted: 9/8/2013 2:58:01 PM : Outperform Start Price: $137.40 ACT Score: +37.60

bought the stock when it was Watson Pharma its been my best performer and i like how its been working

Recs

0
Member Avatar jagad5 (< 20) Submitted: 8/14/2013 11:56:19 AM : Outperform Start Price: $138.04 ACT Score: +38.65

Current price implies a growth rate of 20% while historical growth rate has been 30%.

Recs

0
Member Avatar TerryHoodSr (34.74) Submitted: 1/4/2013 8:44:52 PM : Outperform Start Price: $85.01 ACT Score: +117.22

TP 95

Recs

0
Member Avatar naylorj (68.44) Submitted: 8/3/2012 3:22:58 PM : Outperform Start Price: $79.37 ACT Score: +128.87

EPS Ranking 99

Recs

1
Member Avatar bradford86 (99.78) Submitted: 1/14/2012 2:40:11 PM : Outperform Start Price: $62.79 ACT Score: +190.26

276. Watson Pharmaceuticals (NYSE: WPI) is down from $70 where it topped in 2011. At the present price of around $62, I think that there is a little upside here. Target: $63-$68. My 2012 EPS estimate is $5.60 which puts this at a P/E of 11.1 for a company growing at a double digit clip. Definately looks inexpensive here. Glad to see Bret agrees. I'll be playing CAPS points on this one.

http://beta.fool.com/bradford86/2012/01/14/price-market-part-42/

Recs

0
Member Avatar lting77 (65.34) Submitted: 10/31/2010 9:26:22 PM : Outperform Start Price: $46.85 ACT Score: +292.62

with the purchase of arrow group, is has acquire first to market atorvastatin and partial ownership of eden biodesign, bio generic firm

would not be surprise if teva acquires them after it's done w/ digesting ratiopharm

Recs

0
Member Avatar cashman79 (68.05) Submitted: 9/15/2010 9:55:36 AM : Outperform Start Price: $42.56 ACT Score: +329.01

watch

Recs

0
Member Avatar JDKeene (99.22) Submitted: 8/12/2009 1:01:32 PM : Outperform Start Price: $34.88 ACT Score: +419.46

Ford Strong Buy, S&P (4 or 3 stars), Member of S&P 500

Recs

0
Member Avatar Keithkos1 (< 20) Submitted: 4/25/2009 10:20:35 PM : Outperform Start Price: $32.00 ACT Score: +438.35

big player, sound strategy

Recs

4
Member Avatar stockblog (< 20) Submitted: 9/28/2008 8:10:05 PM : Outperform Start Price: $28.50 ACT Score: +583.97

The generic drug industry is rapidly consolidating amidst a flurry of recent M&A activity -- including the following buyout offers:

Industry leader Teva Pharma (TEVA): buyout bids for Barr (BRL) ($7.5B) & Bentley Pharma (BNT) ($350M)
Sanofi-Aventis (SNY): a $2B bid for Czech-based Zentiva (which has been rejected)
Daiichi-Sankyo (Tokyo: 4568): a $4.6B bid for India-based Ranbaxy (500359)
Fresenius Medical (FMS): buyot of generic injectable firm APP Pharma (APPX) valued at up to $4.6B
India-based Sun Pharma (524715): offer to buy its remaining stake in Taro Pharma (TAROF)
Existing benchmark funds for my Global Generic Drug Index include the pharmaceutical ETFs which contain a mix of biotechs, brand pharma, and generic pharma companies -- including the Pharma HOLDRs (PPH), PowerShares Dynamic Pharma (PJP), iShares Dow Jones US Pharma (IHE), and the S&P Pharma SPDR (XPH). As a pure play index and ETF idea, the global generic drug industry has outpaced all of its drug ETF benchmarks over the past year thanks to widespread M&A, a large number of small/mid-caps, and upcoming key patent expirations for blockbuster brand drugs.

Key patents of multi-billion dollar brand drugs are set to expire within the next few years, including Risperdal and Fosamax in 2008, Prevacid and Topamax in 2009, Lipitor and Effexor XR in 2010, Plavix and Actos in 2011, Singulair and Seroquel in 2012. According to IMS Health statistics, generic medications accounted for 63% of all medications dispensed in the United States in 2006, representing a growth rate of over 22% for unbranded generic drugs. Finally, Momenta Pharma (MNTA) is included in my index as a leader in biogenerics. Momenta has surged nearly four-fold since the rejection late last year on word that the FDA is not requiring additional clinical trials for the generic form of Lovenox, with US sales of $750M in 2007 for Sanofi-Aventis. Momenta also recently filed a patent challenge to produce a generic form of the multiple sclerosis drug Copaxone, which is made by Teva.

Results 1 - 20 of 31 : 1 2 Next »

Featured Broker Partners


Advertisement